Cu Chulainn schreef op 28 maart 2014 21:05:
Hmm, in het 2e deel van het onderstaande stukje wordt duidelijk waarom:
** EXACT SCIENCES CORP, $13.02, -5.31 pct
The company's colon cancer screening method that analyzes DNA from stool samples won the unanimous backing of a U.S. advisory panel on Thursday, paving the way for potential regulatory approval of the non-invasive test.
But Maxim Group analyst Bryan Brokmeier said blood-based tests could limit the market share that Exact Sciences' test could capture and said sales could be limited by the instructions, which might be too complicated for many users in the United States. "I expect that they'll (Exact Sciences) have to make changes to their labeling and refine their post-approval study," he told Reuters.